Management of Large B-Cell Lymphomas: A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-Cell Therapy

Released On
June 14, 2022

Expires On
June 14, 2023

Media Type
Internet

Completion Time
60 minutes

Specialty
Hematology-Oncology Pathology Pharmacy

Topic(s)
Oncology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by The Annenberg Center for Health Sciences at Eisenhower .

 

This activity is supported by an educational grant from Bristol Myers Squibb.

Credit Available

  • Physicians — 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 ANCC Contact Hour
  • Pharmacists — 1.0 ACPE Contact Hour

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

Hematologist-oncologists, pathologists, histologists, advanced practitioners, oncology nurses, pharmacists, and other healthcare professionals involved in the care of patients diagnosed with LBCL.

Program Overview

In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive care management.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review the disease state, clinical and molecular heterogeneity, and unmet needs, including the clinical and healthcare resource burden of LBCL
  • Describe the mechanism of action and appraise available clinical safety and efficacy data and indications for new agents for the treatment of LBCL, especially R/R LBCL, to select optimal treatments
  • Integrate approaches for identifying patients eligible for chimeric antigen receptor T-cell (CAR T-cell) therapy and applying suitable bridging therapies
  • Incorporate approaches for identifying, monitoring, and managing therapy-associated toxicities and AEs, including CAR T-cell–associated toxicities, for patients with LBCL
Jeremy Abramson, MD

Jeremy Abramson, MD

Director, Lymphoma Program
Jon and Jo Ann Hagler Chair in Lymphoma
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Physician Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians

Physician Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.0 contact hour, including 1.0 pharmacology hour, may be earned for successful completion of this activity

Pharmacy Credit Designation

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-0000-22-005-H04-P. This program is designated for up to 1.0 contact hour (0.1 CEUs) of continuing pharmacy education credit.

Disclosures of Conflicts of Interest

It is the policy of the Annenberg Center for Health Sciences at Eisenhower to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals with the potential to impact the content of an accredited education activity are expected to identify and reference off-label product use and disclose relationships with ACCME-defined ineligible companies.

The Annenberg Center for Health Sciences assesses relevant relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant relationships that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Faculty

Jeremy Abramson, MD
  • Advisory Board: AbbVie, Century Therapeutics, Lilly, Mustang Bio, Regeneron
  • Consultant: AstraZeneca, BeiGene, Bluebird Bio, Bristol Myers Squibb, Epizyme, Genentech, Genmab, Incyte, Kite Pharma, Kymera, MorphoSys, Ono Pharma

Additional Content Planners

The following have no signifcant relationship to disclose:
Christopher Elder, PharmD, BCOP (medical writer)
Kam Newman, MD (peer reviewer)
Heather M. Jimenez, FNP-C (nurse reviewer)

Annenberg Center for Health Sciences

All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Instructions for Participation and Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved applications

Disclaimer

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Contact Information

For help or questions about this activity please contact Continuing Education: ce@annenberg.net